Unknown

Dataset Information

0

Serum sickness following rituximab therapy in multiple sclerosis.

ABSTRACT:

SUBMITTER: Holmoy T 

PROVIDER: S-EPMC6927430 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Serum sickness following rituximab therapy in multiple sclerosis.

Holmøy Trygve T   Fogdell-Hahn Anna A   Svenningsson Anders A  

Neurology. Clinical practice 20191201 6

Similar Datasets

Unknown Rituximab for people with multiple sclerosis.
| S-EPMC8574640 | biostudies-literature
Unknown Multiple sclerosis, rituximab, and COVID-19.
| S-EPMC8045943 | biostudies-literature
Unknown Rituximab treatment in pediatric-onset multiple sclerosis.
| S-EPMC11235651 | biostudies-literature
Unknown Self-employment, sickness absence, and disability pension in multiple sclerosis.
| S-EPMC9544424 | biostudies-literature
Unknown Rituximab for the treatment of multiple sclerosis: a review.
| S-EPMC7790722 | biostudies-literature
Unknown Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
| S-EPMC10027934 | biostudies-literature
Unknown Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
| S-EPMC4774261 | biostudies-literature
Unknown Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
| S-EPMC8290177 | biostudies-literature
Unknown Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
| S-EPMC11503085 | biostudies-literature
Unknown Serum hepcidin levels in multiple sclerosis.
| S-EPMC6831977 | biostudies-literature